Audit: QRS - White Atractylodes for Health & Longevity
Audit conducted on 16/08/2026 06:43 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every protocol figure (6–12 g, 5:1 granules 1.2–2.4 g, 2–3 split doses), every benefit and risk heading, all eight biomarker targets, both gate lists and the cadence paragraph trace to ER lines 314–337, 359–388, 408, 434–456, 478–482. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s ⚠️ Conflicted markers are carried as “(conflicted)” on fluid balance, bowel transit and sesquiterpene-lactone genotoxicity; “No established target for this herb” is reproduced verbatim in marker_8_target. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy and breastfeeding stay in the Contraindications gate, not the Interactions gate; “Neither established as superior” reproduces the ER’s own non-committal framing at line 363. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER’s “Populations who should avoid” list (lines 332–337); Key Interactions only from the eight interaction bullets (lines 314–328); no modifying-factor content appears in either gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, no NCT identifiers and no author names; the only named formulas, Si Jun Zi Tang and Shenling Baizhu San, appear in the ER Protocol section at line 361. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No source, institution or investigator is named anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Flat, declarative, caveat-carrying register matching the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantities, thresholds and targets are given precisely while the framing stays neutral and actionable. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells state what is done in practice (“Late-evening dosing is avoided”) rather than instructing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative dosing instruction; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should” or “advise” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Acronyms from the ER are expanded in the gates (“sodium-glucose co-transporter 2 inhibitors”, “non-steroidal anti-inflammatory drugs”); marker names keep the ER’s own parenthetical abbreviations. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefits and Risks are four single-line tier entries each; gate items are stripped to the key fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text search for you/your/yours: no match. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Tight functional biomarker ranges and a 2/6/12-week recheck schedule presume a proactive self-monitoring reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Daily decoction for 20–30 minutes, split dosing, daily symptom logging and repeat blood panels are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The sheet assumes access to laboratory testing and certified sulfur-free material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance leads with the single documented indication and closes on the two structural caveats (never tested alone, routinely sulfur-treated), which is the decision-relevant weighting for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The title uses “Health & Longevity”; the string “anti-aging” does not occur. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Adverse events”, “rhizome”, “decocted”, “hypoglycaemia” are used; the At-A-Glance plain-language wording (“dummy treatment”) is the ER’s own phrasing at line 478 and is required by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings match the template byte-for-byte (lines 445, 492, 543, 578, 597, 634, 663, 667–669, 800 and the eight tier labels). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff of the extracted variable names shows every one of the template’s 34 names present; the only additions are the expected repeat expansions marker_1..8_* and qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three website= spans (evidence_review, audit, full_review) and the footer disclaimer are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source section of the ER is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “Standard pharmacopoeial dose”, action_2_label “Time of day” and action_3_label “Isolated-extract approach” are the ER’s bold labels at lines 359, 365 and 363 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol labels are ER-verbatim; the Time-to-effect cells, for which the ER carries a single “Time to effect” bullet already used as the fixed subhead, use minimal descriptive labels tied to the ER passage each cell condenses. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Search for 🟩/🟥/🟨/⚠ returns no match; the ER’s conflict markers are rendered as the word “(conflicted)”. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Single .sheet container, A4 print rules intact; tier lists collapsed to one line each and gate items stripped to key facts to hold the budget. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the descriptive text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: white_atractylodes_2026-0825-0424_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0816-0633. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual file name white_atractylodes_2026-0825-0424_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “White Atractylodes for Health & Longevity - Quick Reference Sheet”, matching ER frontmatter canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “White Atractylodes for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/16/2026, the correct reformat of 2026-0816-0633. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header holds only the title and the template’s own subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 478–482: classical use, the one documented effect, the weaker signals, and the two structural caveats. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 53 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct Conclusion passage at ER lines 478, 480 and 482. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “Root-stem”, “daisy-family plant”, “loose stools”, “dummy treatment”, “blood fats”, “gut bacteria”, “sulfur-treated” — no acronym and no specialist register. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Only qualitative direction words (“more relief”, “weaker signals”); no numbers. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from the “Populations who should avoid White Atractylodes” list at ER lines 332–337. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 581–592: six discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | “despite the classical indication — modern uterine smooth-muscle activity…” (ER 332) and “where any transporter interference is unacceptable” (ER 337) are both stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Stage 4, eGFR <30 mL/min/1.73 m², potassium >5.0 mmol/L, the 14-day surgical window, platelets <100 × 10⁹/L and the daisy-family example list are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names six such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one to the ER interaction bullets at lines 314–328. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interactions carried; none duplicates a Contraindication entry. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 600–624: eight discrete <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “Caution. … Mitigation: …” tail from the ER bullets is stripped; only the drug-class label and its example list remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All eight example-drug lists are preserved; the ER’s inline definitions (“which push the pancreas to release insulin”, “drugs such as domperidone that speed gut transit”) are trimmed while the drug names survive. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER lists eight interactions, and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells draw on the ER Therapeutic Protocol bullets at lines 359–367. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose and preparation, timing and dose splitting, and the formula-versus-isolate decision are the three implementation choices a user must actually make. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER’s Therapeutic Protocol section carries ten bullets, well above three. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content: 6–12 g and 5:1 granules (ER 359), pre-meal timing and two-to-three dose split (ER 365, 367), and the non-superiority of either preparation approach (ER 361, 363). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Minimum read-out at 4 weeks, a fair 8–12 week trial, and the 4-week reassessment pause are the three temporal decisions the ER supports (lines 382, 388, 408). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | time_1 attaches to the High-tier bowel-symptom benefit; the later cells widen from that anchor to overall trial length and reassessment. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct temporal aspects are present and all three cells are filled. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “4 weeks minimum” (ER 408), “8–12 weeks” (ER 382, 408), “4 weeks off after 8–12 weeks on” (ER 388), each with an ER-sourced sub-line. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet at line 408, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten entries correspond to the ten ER benefit headings at lines 158–220. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 545, 551, 557, 565. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER heading text survives; the relative risks (1.94, 1.41, 1.18), confidence intervals, numbers needed to treat and trial counts are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No effect size, sample note or study reference is carried; the sole parenthetical, “(conflicted)”, is the plain-text rendering of the ER’s ⚠️ Conflicted heading marker that items 1.2 and 4.4 together require. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain at least one item. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All nine entries correspond to the nine ER risk headings at lines 242–296. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 636, 639, 645, 652. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The relative risks (1.33, 1.05), numbers needed to harm, the 1.2%/3,679 patch-test figures and the IC50 are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No frequency, grade or study detail is carried; the two “(conflicted)” markers reproduce the ER’s ⚠️ Conflicted flags on bowel transit and sesquiterpene-lactone genotoxicity. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain at least one item. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows reproduce the ER biomarker table at lines 438–447. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present with matching targets: potassium, sodium, ALT, fasting glucose, HbA1c, platelet count, hs-CRP, plasma aldosterone. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 789–794 reproduce the ER cadence paragraph at line 436, including the 2/6-week potassium checks, 12-week full panel, 6–12-month interval and the three-month rule for co-medicated users. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER qualitative-marker list at lines 451–456. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present: stool frequency/Bristol form, abdominal pain 0–10, appetite and post-meal fullness, daytime energy, bloating, and new bruising/bleeding/dizziness/rash. |
Issues 16/08/2026 06:43
Pass rate 100.00%. No issues found.
Issues 16/08/2026 06:38
- 4.2 / 4.3 — Invented protocol cell label:
action_3_label(line 477) reads “Formula or isolated extract”, a merged, invented label; the ER Therapeutic Protocol section uses the bold labels “Conventional formula approach:” and “Isolated-extract approach:”, one of which must be carried verbatim.
Fixes 16/08/2026 06:38
- 4.2 / 4.3 — Verbatim ER label for protocol cell: Changed
action_3_labelfrom the invented “Formula or isolated extract” to the ER’s bold label “Isolated-extract approach”, and reorderedaction_3_subto lead with the isolate approach so the cell body matches its label.